Scholars Central

Conference abstract

Metformin targets mammary/cancer stem cells in breast cancer prevention and treatment

Authors: Xiaohe Yang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Increasing evidence suggests that targeting cancer stem cells (CSCs)/tumor-initiating cells (TICs) is a promising approach to treat and prevent cancer diseases. Recent advances indicate that use of metformin, a common anti- diabetes drug, is associated with reduced risk of breast and other types of cancers. However, the mechanisms of metformin mediated anticancer activities remain unclear. ErbB2/Her2 amplification in breast cancer has been associated with poor prognosis and therapeutic resistance. It was sought to determine the effect of metformin on CSCs/TICs in ERBB2 tumor models. In vitro results showed that metformin has potent anti-proliferative effects on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1R interactions. Using mammary tumor virus (MMTV)-ErbB2 transgenic mouse model, it was demonstrated that systemic administration of metformin to these mice during the premalignant risk window selectively inhibited the CD61 (high)/CD49f (high) mammary epithelial cells. Cells with this phenotype had been identified as luminal progenitor cells and may function as TICs during tumor development in MMTV-ErbB2 mice. It was further demonstrated that metformin also inhibited CD61 (high)/CD49f (high) subpopulation in ErbB2 tumor-derived cells in vitro and tumor development in a syngeneic tumor graft model. Mechanistic studies indicated that metformin inhibited the expression and activation of ErbB family members and IGF-1R, AKT/mTOR signaling, and STAT3, c-myc associated activities. In vitro data also showed that low doses of metformin inhibited the self-renewal/proliferation of cancer stem cells (CSCs)/TICs in ErbB2-overexpressing breast cancer cells. Results provide fundamental support for developing metformin-mediated preventive strategies targeting ErbB2- associated carcinogenesis.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Xiaohe Yang”